Novo Nordisk filed suit against another semaglutide compounder on Friday, bringing its total number of cases to 50. Both Novo ...

Novartis used one of its priority review vouchers (PRV) to speed the September approval of Kisqali in early breast cancer, ...

Private equity firms TPG and Blackstone are working on a potential deal to buy Brent Saunders-led eye care company Bausch + ...

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...

The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant ...

More than a year ago, Endpoints News made the decision that we needed a dedicated reporter covering the use of artificial ...

KIT antibody has shown promise in a Phase 1b/2a test in people with certain irritable skin conditions, sending its shares ...

After flashing warning signs in July with only enough money for that month, Inventiva has now secured a lifeline to keep its ...

Novartis has terminated a mid-stage trial of an oral treatment candidate for idiopathic pulmonary fibrosis, the company ...

Seven years ago, Daniel Ives believed that he was on the cusp of solving aging. He wanted to continue working on a discovery ...

Eli Lilly plans to invest £279 million ($364 million) in the UK as part of a new government partnership in which the drugmaker will bring its Gateway Labs overseas for the first time. The pharmaceutic ...

Transgene’s therapeutic cancer vaccine candidate has failed a mid-stage test in certain HPV-driven cancers, sending its ...